Result card

  • ECO2: What quantity of resources is used when delivering uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® and what quantity of resources are used when delivering standard clinical practice?
Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX )
E0002
English
Guidance Resources

What quantity of resources is used when delivering uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® and what quantity of resources are used when delivering standard clinical practice?

Authors: Isaura Vieira, Mirella Corio, Maria Rosaria Perrini, Matteo Ruggeri

Internal reviewers: Hanan Bell, Marco Oradei, Michelle O'Neill, Patricia Harrington, Kristi Liiv

Selected studies extracted from the basic literature search were analysed. Eight studies {1; 2; 3; 4; 5; 7; 8; 9} were found to be relevant to this question.

The quantity of resources used, excluding the resources associated with the delivery of the prognostic tests, will be highly dependent on the distribution of patients over the risk profiles and on the distribution of the duration in each of the different health states. Thus the amount of resources used, after the risk of recurrence profile distribution (using the prognostic tests or standard of care), will need to be modelled separately for each of the treatment scenarios and patient health states.

A number of the studies selected and analysed describe the quantity of resources used in their models {2; 3; 4; 5}. These estimates of resource utilisation were based on different sources of information including treatment guidelines, observational studies, and retrospective studies leading to different estimates of overall resource utilisation in different studies.

This variability, based on the inconsistency of the data, could be reduced with further high quality evidence from randomised controlled trials (RCTs) as discussed in the EFF domain.

Due to the limitations referred to in the domain introduction, the objective here is to prepare a rough description of the structure of an economic evaluation. It was not considered appropriate to present the unit costs for each resource identified.

Critical
Partially
Vieira I et al. Result Card ECO2 In: Vieira I et al. Costs and economic evaluation In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=113

References

  • {1}   Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value in Health. 2010; 13(4).
  • {2}  Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer inJapan. Breast cancer research and treatment. 2008; 112(1): 175-187.
  • {3}  Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast cancer research and treatment. 2011; 127(3): 739-749.
  • {4}  Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist. 2010; 15(5): 457- 465.
  • {5}  Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. European Journal of Cancer. 2010; 46(8): 1382 - 1391.
  • {7}  Vanderlaan BF, Broder MS, Chang EY, Oratz R, Bentley TG. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. American Journal of Managed Care. 2011 July; 17(7): 455- 464.
  • {8}  Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. American Journal of Managed Care. 2005 May; 11(5): 313 – 324.
  • {9}  Bacchi CE, Prisco F, Carvalho FM, Ojopi EB, Saad ED. Potential economic impact of the 21-gene expression assay on the treatment of breast cancer inBrazil. Revista da Associacao Medica Brasileira. 2010; 56(2): 186 – 191.